A Study of LY4515100 in Healthy Participants

Summary

The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. LY4515100 will be given by itself or with other medicines. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will have 3 parts and will last about 50 days. For each participant in Part A, the study will include a stay in the Clinical Research Unit (CRU) lasting about 6 days. For each participant in Part B, the study will include a stay in the CRU lasting about 15 days. For each participant in Part C, the study will include up to 2 stays in the CRU each lasting between 7-28 days.

Conditions

• Healthy

Interventions

DRUG

LY4515100 via SAD

given orally

DRUG

LY4515100 via MAD

given orally

DRUG

LY4515100

given orally

DRUG

Itraconazole

given orally

DRUG

Caffeine

given orally

DRUG

Digoxin

given orally

DRUG

Iohexol

given IV

DRUG

Metformin

given orally

DRUG

Rosuvastatin

given orally

DRUG

Placebo

given orally

Sponsors & Collaborators

• Eli Lilly and Company

  lead INDUSTRY

Principal Investigators

• Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2026-01-15

Primary Completion

2027-03-31

Completion

2027-03-31

FDA Drug

Yes

Countries

• United States

Study Locations